Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline Review, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline Review, H1 2017


  • Products Id :- GMDHC9361IDB
  • |
  • Pages: 69
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline Review, H1 2017, provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape.

Homozygous familial hypercholesterolemia is a genetic disorder which is caused due to mutation from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain and sores on the toes that do not heal. Treatment includes diet changes and statin drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 7, 1, 3 and 1 respectively.

Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Homozygous Familial Hypercholesterolemia (HoFH)-Overview

Homozygous Familial Hypercholesterolemia (HoFH)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Homozygous Familial Hypercholesterolemia (HoFH)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Homozygous Familial Hypercholesterolemia (HoFH)-Companies Involved in Therapeutics Development

CymaBay Therapeutics Inc

Daewoong Co Ltd

Gemphire Therapeutics Inc

LipimetiX Development Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

The Medicines Company

Homozygous Familial Hypercholesterolemia (HoFH)-Drug Profiles

AEM-28-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2802-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2814-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alirocumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

evinacumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gemcabene calcium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inclisiran-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGL-3196-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGL-3745-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGX-501-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seladelpar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-103-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Homozygous Familial Hypercholesterolemia (HoFH)-Dormant Projects

Homozygous Familial Hypercholesterolemia (HoFH)-Product Development Milestones

Featured News & Press Releases

Apr 06, 2017: Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia

Mar 14, 2017: The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17

Jan 30, 2017: Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial

Jan 05, 2017: Gemphire Therapeutics Provides Clinical Update

Dec 19, 2016: Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study

Sep 26, 2016: Gemphire Therapeutics Enrolls First Patient in the COBALT-1 Trial Investigating Gemcabene in Homozygous Familial Hypercholesterolemia

May 31, 2016: Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Mar 17, 2016: CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia

Apr 23, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia

Mar 25, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by CymaBay Therapeutics Inc, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Daewoong Co Ltd, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Gemphire Therapeutics Inc, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by LipimetiX Development Inc, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by RegenxBio Inc, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by The Medicines Company, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH)-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

CymaBay Therapeutics Inc, Daewoong Co Ltd, Gemphire Therapeutics Inc, LipimetiX Development Inc, Regeneron Pharmaceuticals Inc, RegenxBio Inc, The Medicines Company

select a license
Single User License
USD 2000 INR 138000
Site License
USD 4000 INR 276000
Corporate User License
USD 6000 INR 414000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com